

Foundation Medicine reports are tailored to regional needs and so may differ from the example shown.

## **Example report**



Biomarker findings. TMB and MSI status, which may predict response to immunotherapy

Genomic findings. Clinicallyrelevant alterations in >300 tested cancer-related genes Pertinent negative results. Rules out important alterations that are not present

Therapies with clinical benefit. Approved therapies for your patient's biomarkers and genomic alterations Clinical trials. Relevant trials that your patient may be eligible for, based on their genomic profile and geographic location

Genomic findings with no reportable options. To help you rule out uncertainty and determine the most appropriate course of action





		BOMARCE FROM	8	
umenete Tumor Mutational Burden Neternendiate (11 Muts/Web				
Microsatellite status censess MS-Stable				
former de Specifiquel que time activité de la completación de	telepiteter II Komin 311 Sanja Paga Sanja Ko	where the largest in, the force (percentings the other where percent applies the largest in the conversion of the other where the other many 3 of	10.00	

FOUNDATION**ONE®CDx** 

Ang Juliy associates EGR angeleates, 1918			Ausg Balaya sawakana Yanana Mudahaada Badana Yanti menendaka (Yana) yana	
			Anny Johny association EGTR angulocation, 1200	
Ang Johng assession Tamor Mutational Bunders Telebonenedule (1900k, 900				
	12-12-12-12-12-12-12-12-12-12-12-12-12-1	And a second second		

Gives important background information on **biomarkers and** genomic alterations in your patient's tumour, notably the evidence behind associated potential treatment strategies.

Provides evidence-based insights on the therapies that match your patient's profile, in their tumour type and others.

80.00003	CLINICAL TRIALS	0.0710 2003000000			APPENDIX Variants of Unknown Sig	Cance	orra XXXXXXXXX		APPEN	Genes assayed in	FoundationOne <sup>++</sup> CDx
Here a second seco	will more closed with resolutions contents. To additional advantation about based closes within at the content is a word? for additional with closes we close additionages		ariants of unknown significance (VUS) wen stars at the time this report was issued, and the event that they become clinically mean		hose variants may not have been adequately chara bostions makes their significance undear. We ch	tand to	FoundationOne CDv is designed to include generapproved or in clinical trials, and/or that are una well as introns of all genes involved in marranger	bigaous drivers of encogreesis	based on current knowledg	or. The current assay intere-	ogates 324 genes as
umor Mutational urden	Willer.	AKT3 E3320	EP300 5121, 524L, and 526F	IRS2 M543L and R1285Q	LRP1B CTT99F		DNA. GENEL LET: INFERE CODING SEQUENCE   AND COPY INVEREE ALTERATIONE   ALEI ACVESIS ACTI   ALEI ACVESIS ACTI   ALE ACVESIS ACTI   ALE ACVESIS ACTI   ALE ACVESIS ACVESIS   ALE ADVI ALE   ADVID ALE ADVID   ADVID ADVID ALE   ADVID ADVID ALE   ADVID ADVID ALE   ADVID ADVID ADVID   ADVID ADVID ADVID   ADVID ADVID ADVID   ADVID ADVID ADVID   ADVID CONID CONID   CONID CONID CONID   CONID CONID CONID   CONID CODIN CONID	AKT2 AKT2 AST891 AEDA BAPI BAR21 BECA1 BECA2 CAR CAR211 C322 C3211 (PD C365 C316	ALK AL AGALI AT BCLJ BC BCLJ BC BCLJ BC CASPR CR (CASPR CR	01128 ATRX M ATR 1241 BC2322 FI BC2 FI CE FI C C CE FI	AMERI (FAMI228 AURA BCL6 BTG2 CONDI CDC72 COND8 CSF28
C75048078	PRASE 3						CTCF CTNNAI CTNNAI DOR2 DG2 DAMT2A	0.82 0.64A 0071 80		PIZAI DAXX	0.081 EPH81
	1486(75 PD-61						EPHIN ERBEZ ERBEZ FAMINE FANCA DAVIC FEETH FEETIN FEETIN	PRBM PRCCA PANCE PANCE REF3 REF4	185 18 745 78 7574 75	801 ESR XW7 RGRD RE RGRD	1250 AGRQ AGRQ
COURSE Recognized from Andrianity Review Services Review							GERM EN R.CN GADNA GADNA GANNI	ATI ATI Quat Quag	FORL2 FLI GANS GR	10 65438	GATA3 HOTA
Tribulation Technic	Puese a						HEHEI HEF HHFU HEHE HEFT HPHE	ARAS ASDAH RC2 RF4	101 101 RD 144	10 JAI2	JAK2
And the state of the second seco	PO-L1						JUN KÜMESA KÜMESC KAITZA (MLL) KAITZO (MLLZ) KAIS MARZIT MARZITZ MARZIT MIRTIK MIT MIT	KDIMA KDR LTK DN MCLI MDM2 MKHZ MEH	MOMI MS		KLHEG EK2) MAP2K4 MEN1 MEN2
and the second lock long the size here, they have							MSHL MSTR MEAP MRN NFT NF2	MEDR MUTHW NEE212 NEEBA	NO2-1 NO	ICL (MVCLI) MVOV	MYD88 NDT042
1940 T 1980	P0038.3						NPMI NRAS NISC2 PARPI PARP2 PARP2 PDMI PICK28 PICK26	NTRKI NTRK2 IAXS PERM		CONST (PO-L2) POGRA	ANRK2 POGERB
and the second of the second states of the	Taelog TS PD-1						POLE PENES PERSIA FIDMI FIDMO OKI	PICOCA PICOCE PIPORDA PICOMI RACI RACOI	PRKARSA PRI RADGI RA	KC PTCHI DON RADOLC	POLDI PTEN RADGID
strike the stag, both paths fromplants have like but because the liters							RADIZ RADIGE RAFT RAFAZ ROST RFTOR SCRI SMADI SMADA	AADA ADD SDAA SDAB QAADA'AA QAADA'DI	88M10 82 524C 52 540 54	60 56132	RICTOR
Television	Provide B						50KI 58M20 58M24 50X9 595N 590P 1932 10K 1012	SKARCAN SKARCEI SIC STAG2 TIGTER2 TIMEP	53473 53	CNP SOCSI KII SURU FRSFM TPSI	501/2 51K TSCT
And the second se	Tuesdats CTLA-6, PD-1						1862 INK INI 1552 THR02 LOAFI 18622 ZNQ17 ZNV782	NEGEN INC		KSCILI W71	XP01
content water and a foregroup loss, but having the last							DNA GENE LIST: FOR THE DETECTION OF SEL	************************************			
CTRANSING IN	Penal 2						ALK BCL2 BCR ETH ETHS ETHS	BRAF BRCAI DVSRI 528	BRCA2 CD FGFRI FG		EGFR KMT2A.(MUL)
And the function of the part o	TARGETS CTLA-4, PD-1						MSA2 MYR MYC RARA RET R251 'TERC's and RMA	NOTCH2 NTREI RSP02 SDC4		ITMI POGRA	RAFI TMPRSS2
server along the second formation because the set of the local	Constant No. No. 1						"The promular region of TBET interrogated				
							ADDITIONAL ASSAYS FOR THE DETECTION O MICRUSHER UTLIK (MS) Turnor Mutational Bunder (TMR)	SELECT CANCER BOMARK	es		
nan styl fynally i dy'r llan 10, 10, 10, 1 safny 5 km, k.C. Nador Danter 10 Koannar (10 Anna malwr, yn 1 10, 10, 10) Sagar	nervines the local state of the spectra of the spec	Decisionally Speed by Sciences, Inc.	in A. Boles, M.Z., 1962. • Jeffery V. Bares, M.D., Marshard Zoreck 9 4880–9830 9	- 33 fearaine 2017 - Lan	gla Programfina 103 Incord 10, 34 Ferry, Cardwidge 104 (2011) - angla Backgale 103 Incord 10, 34 Ferry Cardwidge 104 (2012) - 14 (2010) 102 - 140		Distinctionally Egymetricy India A. Evin, H.C., Ph.L. + Mellowy L. Barn, J. Namadatian Machines, Inn. + 5 (2019) 10231	D, Medical Director + 3D Nonreller 2017	Lample Posparulis Lample Analysi	an 100 Second St., No Time, Cambri In 100 Second St., No Time, Cambri Annual	ар, ма сонг-сил 11000 ар, ма сонг-сил 11000 мож — раде 20 об
					APPENDE - PRO				7		
ails <b>ongoing clinic</b>	al trials that	Lis	sts <b>varia</b>	nts of	unknowi	_	Talla vou	hat		to d +	
	aliailala fau		161	- 0/110	المنام منارك	al	Tells you <b>w</b>	nat w	e tes	tea t	o gi
ur patient may be	eligible for,	SIG	mcance		5), include	a	you a com				

with trial NCT number, phase, title and locations.

in the event that they become clinically meaningful in the future.

our service.

## FOR FURTHER DETAILS PLEASE CONTACT YOUR LOCAL AFFILIATE Visit rochefoundationmedicine.com

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine®, Inc. Roche is the licensed distributor of Foundation Medicine® products outside of the United States

